There is substantial experience attempting to treat KRAS-mutated lung adenocarcinoma with the use of RAS/RAF multikinase inhibitors as well as inhibitors of both upstream and downstream proteins important in RAS signaling. We review the disappointing results from these clinical trials in lung cancer. ...
2025年1月6日,中国医学科学院肿瘤医院石远凯教授团队在nature medicine发表题为“Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial”的研究。该研究旨在评估glecirasib在局部晚期或转移性KRASG12C突变NSCLC患者中的疗效和安全性。研究结果表明glecirasib在这些患者群体中表现出良好的临床...
[3]Wouter W. Mellema, et al.Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Lung Cancer. 2015 Nov;90(2):249-54. [4]Anna Ketal.Survival outcome according to KRAS mutation status in newly diagnos...
garsorasib是一种有效的KRASG12C抑制剂,在KRASG12C突变(即Gly12Cys)非小细胞肺癌(NSCLC)患者的1期研究中显示出有希望的抗肿瘤活性。 2024年6月10日,上海交通大学陆舜团队在 Lancet Respiratory Medicine(IF=76)在线发表题为“Garsor...
1.Dy GK, Govindan R, Velcheti V, et al. KRAS Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol, 2023, undefined: JCO2202524. ...
2025年1月6日,中国医学科学院肿瘤医院石远凯教授团队在nature medicine发表题为“Glecirasib inKRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial”的研究。该研究旨在评估glecirasib在局部晚期或转移性KRASG12C突变NSCLC患...
[1] Li Z, Dang X, Huang D, et al. Garsorasib in patients with KRAS-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2024 Jun 10:S2213-2600(24)00110-3. doi: 10.1016/S2213-2600(24)00110-3. Epub ahead of ...
In KRAS-mutated tumours, other oncogenes or tumour suppressor genes may also be abnormal and may participate in immune escape together with KRAS mutation. For example, in lung cancer, coactivation of KRAS (G12D) and MYC drove the aggregation of anti-inflammatory macrophages, but the absence of...
期待更多国研好药早日获批,落地医保,造福更多国内的肺癌患者。 参考资料: Yeh J, Marks JA, Alzeer AH, et al. Remarkable intracranial response to sotorasib in a patient with KRASG12C-mutated lung adenocarcinoma and untreated brain metastases: a case report. JTO Clin Res Rep. 2022;3:100428....
参考文献: J. Baptiste Oudart, S. et al., STK11/ LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial, Lung Cancer (2024). 发布于 2024-03-01 18:04・IP 属地北京 ...